Objective,2,To evaluate the efficacy and safety of Yiqi Yangyin Jiedu （YQYYJD） regimen of traditional Chinese medicine（TCM） plus anlotinib for advanced non-small cell lung cancer （NSCLC）.,Methods,2,A retrospective study approach was applied to collect information on advanced NSCLC cases treated with the YQYYJD regimen of TCM plus anlotinib from June 2018 to March 2021 through the electronic medical record system. All cases were followed up until November 1， 2021， and general information such as driver gene mutation， previous treatment， and pathological types were recorded to evaluate the outcome of solid tumors， and changes in Eastern Cooperative Oncology Group （ECOG） score and the incidence of adverse events were analyzed. Median progression free survival （PFS） and median overall survival （OS） were calculated by the Kaplan-Meier method. Cox analysis was used to evaluate the significance of factors influencing PFS and OS.,Results,2,①A total of 33 cases of advanced NSCLC treated with YQYYJD regimen of TCM plus anlotinib were included in the study， and 12 cases harbored driver gene mutation. All patients had previously received epithelial growth factor receptor tyrosine kinase inhibitor （EGFR-TKI）， anaplastic lymphoma kinase tyrosine kinase inhibitors （ALK-TKI）， or first- and second-line chemotherapy， and acquired resistance， and 20 patients progressed after at least two lines of chemotherapy. The median line of therapy for anlotinib was three. ②The median progression free survival （PFS） was 7.0 months （95% CI： 2.7-11.3）， and the median overall survival （mOS） was 16.0 months （95% CI： 12.4-19.6） in 33 cases. ③In evaluating best outcomes of solid tumors， there were 3 cases of partial response， 29 cases of stable disease， and 1 case of disease progression， with an objective response rate of 9.1% and a disease control rate of 97.0%. ④During the treatment， only 1 case of grade 3 treatment-related adverse effects （renal impairment） and reduced dose of anlotinib was reported. ⑤During the course of treatment 22 cases （66.7%） reported stable performance status. ⑥Cox multifactorial analysis demonstrated that elevated TSH level after treatment was significantly associated with longer PFS （RR=3.971， 95% CI： 1.524 - 10.347， ,P,=0.005）， and no independent prognostic factors related to OS was found； The mPFS of patients with elevated TSH after treatment was 12 months， longer than that of patients without elevated TSH （ mPFS was 5 months） （RR=0.197， 95% CI： 0.067 - 0.574， ,P,=0.002 9）.,Conclusion,2,YQYYJD regimen of TCM may prolong survival of advanced NSCLC patients by reducing adverse effects of anlotinib and stabilizing general performance status.